Synthon is announcing today that it has successfully concluded multiple registration procedures for the cardiovascular drug eplerenone. Synthon has obtained regulatory clearance for the product in nine European countries, for both 25 and 50 mg film coated tablets.
Synthon's eplerenone is a fully generic and bioequivalent version of Pfizer’s Inspra® tablets. European sales of eplerenone were 109 million Euros (MAT June 2011) based on IMS Midas data. Synthon’s eplerenone is part of a rich pipeline of research projects and pending regulatory applications.
* Inspra® is a trademark of C.P. Pharmaceuticals International C.V.
Synthon, with headquarters in Nijmegen, the Netherlands, is an international fast-growing pharmaceutical company and a leader in the field of generic medicines. Synthon has been working in biotechnology since 2007 and is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of Multiple Sclerosis and Oncology. Synthon employs more than 1,300 staff at 11 sites worldwide, and in 2010 it recorded a turnover of EUR 230 million. For more information, go to www.synthon.com.